Scarica l'app Stockscreener
21.73
2.31%
0.49
Pre-mercato:
21.55
-0.18
-0.83%
Precedente Chiudi:
$21.24
Aprire:
$21.28
Volume 24 ore:
710.85K
Relative Volume:
0.83
Capitalizzazione di mercato:
$893.10M
Reddito:
$681.75M
Utile/perdita netta:
$70.47M
Rapporto P/E:
14.99
EPS:
1.45
Flusso di cassa netto:
$173.19M
1 W Prestazione:
+5.08%
1M Prestazione:
-7.65%
6M Prestazione:
-13.74%
1 anno Prestazione:
-20.26%
Intervallo 1D:
$20.88
$22.02
Intervallo di 1 settimana:
$20.23
$22.02
Portata 52W:
$18.80
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Nome
Pacira Biosciences Inc
Settore
Telefono
650-242-8052
Indirizzo
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
21.73 | 872.96M | 681.75M | 70.47M | 173.19M | 1.45 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Equal Weight |
| 2025-11-17 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-25 | Aggiornamento | Truist | Hold → Buy |
| 2025-01-30 | Aggiornamento | Truist | Sell → Hold |
| 2024-08-13 | Downgrade | Truist | Buy → Sell |
| 2024-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Ripresa | JP Morgan | Overweight |
| 2023-12-20 | Iniziato | Raymond James | Outperform |
| 2023-08-03 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Ripresa | Wedbush | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-01-03 | Ripresa | JP Morgan | Overweight |
| 2021-07-26 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Ripresa | JP Morgan | Neutral |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-04-07 | Iniziato | Northland Capital | Outperform |
| 2020-03-20 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-24 | Iniziato | SunTrust | Buy |
| 2020-01-23 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Iniziato | BTIG Research | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-06 | Aggiornamento | Mizuho | Underperform → Neutral |
| 2019-05-02 | Aggiornamento | Stifel | Sell → Hold |
| 2019-02-01 | Downgrade | Mizuho | Neutral → Underperform |
| 2018-08-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-21 | Reiterato | Mizuho | Neutral |
| 2018-02-16 | Downgrade | Needham | Buy → Hold |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2018-01-04 | Reiterato | Canaccord Genuity | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Mkt Perform |
Mostra tutto
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Pacira BioSciences, Inc. $PCRX Holdings Raised by Impax Asset Management Group plc - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Pacira (PCRX) Issues Inducement Awards to New Employees Under 20 - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Pacira BioSciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Pacira BioSciences: Mispriced On Generic Risks That Are Years Away (NASDAQ:PCRX) - Seeking Alpha
2026-02-08 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect | NDAQ:PCRX | Press Release - Stockhouse
NJ Judges Tosses Pacira Investor Suit Over Patent Loss - Law360
2026-02-05 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out | NDAQ:PCRX | Press Release - Stockhouse
Avoiding Lag: Real-Time Signals in (PCRX) Movement - Stock Traders Daily
Pacira BioSciences (PCRX) Stock Price, News & Analysis - MarketBeat
Pacira BioSciences SVP Lauren Riker sells $83k in stock By Investing.com - Investing.com Nigeria
Pacira BioSciences SVP Lauren Riker sells $83k in stock - Investing.com
Pacira BioSciences (NASDAQ:PCRX) SVP Lauren Riker Sells 4,000 Shares - MarketBeat
Pacira BioSciences officer Williams sells $269k in shares By Investing.com - Investing.com Canada
Pacira BioSciences officer Williams sells $269k in shares - Investing.com
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Unlocking a 40% Potential Upside in Non-Opioid Pain Management Solutions - DirectorsTalk Interviews
2026-02-01 | Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Great Lakes Advisors LLC Decreases Stake in Pacira BioSciences, Inc. $PCRX - MarketBeat
In A Strategic Move, Samit Hirawat Acquires Pacira BioSciences Stock Options Worth $9K: Enhancing Value - Benzinga
Gagnon Securities LLC Grows Stock Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Gap Down: What is Deluxe Corporations valuation compared to sectorQuarterly Trade Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Pacira BioSciences appoints Samit Hirawat to board of directors By Investing.com - Investing.com Nigeria
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
What are Pacira BioSciences Inc.’s technical support levels2025 Sector Review & Technical Buy Zone Confirmations - mfd.ru
Pacira appoints Samit Hirawat to board of directors - TipRanks
Bristol Myers Squibb (BMY) Exec Joins Pacira BioSciences Board - GuruFocus
Pacira BioSciences appoints Samit Hirawat to board of directors - Investing.com
Bristol Myers drug development leader joins Pacira board - Stock Titan
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors - Sahm
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect - ACCESS Newswire
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Unveiling a 44.95% Potential Upside for Investors - DirectorsTalk Interviews
Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report? - Finviz
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Discipline and Rules-Based Execution in PCRX Response - Stock Traders Daily
Volume Recap: Is Pacira BioSciences Inc a good ESG investment2025 Big Picture & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Pacira partners with LG Chem to make EXPAREL® available in select APAC markets - BioSpectrum Asia
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Will Pacira BioSciences Inc. stock deliver shareholder valueDebt-to-Equity Ratio Analysis & Smarter Trades Backed by Machine Learning - bollywoodhelpline.com
DOMA Perpetual Capital to offer nominees for Pacira BioSciences board - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive - simplywall.st
Benign Growth For Pacira BioSciences, Inc. (NASDAQ:PCRX) Underpins Stock's 28% Plummet - 富途牛牛
Pacira BioSciences Inc (PCRX) Stock Price Down 5.4% on Jan 16 - GuruFocus
Market Outlook: Is Great Elm Group Inc subject to activist investor interestPortfolio Performance Summary & Smart Swing Trading Alerts - baoquankhu1.vn
Pacira BioSciences (NASDAQ:PCRX) Hits New 52-Week LowTime to Sell? - MarketBeat
Do Options Traders Know Something About Pacira BioSciences Stock We Don't? - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - accessnewswire.com
Pacira Biosciences Inc Azioni (PCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):